You are here
TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CA130030
Agency Tracking Number: N43CA130030
Amount:
$200,000.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Timeline
Solicitation Year:
2013
Award Year:
2013
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
GENESEGUES, INC.
3180 HIGH POINT DRIVE
CHASKA, MN
55318-9476
United States
DUNS:
95972415
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: GRETCHEN UNGER
Phone: (952) 443-3798
Email: GMU@GENESEGUES.COM
Phone: (952) 443-3798
Email: GMU@GENESEGUES.COM
Business Contact
Name: GRETCHEN UNGER
Phone: (952) 443-3798
Email: GMU@GENESEGUES.COM
Phone: (952) 443-3798
Email: GMU@GENESEGUES.COM
Research Institution
Name: Stub
Abstract
The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer. PUBLIC HEALTH RELEVANCE
* Information listed above is at the time of submission. *